← Back to All US Stocks

Lifevantage Corp (LFVN) Fundamental Analysis & AI Grade 2026

LFVN Nasdaq Pharmaceutical Preparations CIK: 0000849146
Updated This Month • Analysis: May 7, 2026 • SEC Data: 2026-03-31
Combined AI Grade
B
64% Confidence
STRONG AGREEMENT
B
62% Conf
B
66% Conf

📊 LFVN Key Takeaways

Revenue: $140.2M
Net Margin: 2.7%
Free Cash Flow: $2.9M
Current Ratio: 1.96x
Debt/Equity: 0.00x
EPS: $0.30
AI Grade: B with 62% confidence
Lifevantage Corp (LFVN) receives a B fundamental grade with 64% confidence from our AI analysis based on SEC 10-K filings. With revenue of $140.2M, net profit margin of 2.7%, and return on equity (ROE) of 11.4%, Lifevantage Corp demonstrates mixed fundamentals in the Healthcare sector. Below is our complete LFVN stock analysis for 2026.

Is Lifevantage Corp (LFVN) a Good Investment?

Claude

Lifevantage demonstrates solid revenue growth of 14.2% YoY and maintains an exceptional gross margin of 77.4%, supported by a fortress balance sheet with zero debt and positive free cash flow. However, severe margin compression (77.4% gross to 3.2% operating) raises material concerns about cost structure and operational efficiency, resulting in anemic 2.7% net margins that limit profitability despite strong top-line performance.

ChatGPT

Lifevantage is posting double‑digit revenue growth with a very strong gross margin and a debt‑free balance sheet, indicating improving fundamentals and financial resilience. Yet profitability remains thin and free cash flow is negative, signaling that earnings quality and working‑capital discipline must improve. Sustained margin expansion and conversion of earnings to cash are needed before a more constructive stance.

Lifevantage Corp Key Strengths (LFVN)

Claude
  • + Revenue growth of 14.2% YoY shows market traction
  • + Exceptional gross margin of 77.4% indicates strong product economics
  • + Zero long-term debt with debt/equity ratio of 0.00x provides financial flexibility
  • + Positive free cash flow of $2.9M demonstrates cash generation capability
  • + Strong liquidity position with 1.96x current ratio and $12.5M cash reserve
  • + Positive ROE of 11.4% and ROA of 6.1% show capital productivity
ChatGPT
  • + Debt‑free balance sheet with solid liquidity (current ratio 2.03x)
  • + High gross margin of 76.7% indicating strong unit economics
  • + Revenue and net income growing YoY (+14.2% revenue, profitability rebound)

LFVN Stock Risks: Lifevantage Corp Investment Risks

Claude
  • ! Severe 44.2 percentage point margin compression (gross to operating) indicates unsustainable cost structure or excessive operating expenses
  • ! Net income of only $3.8M on $140.2M revenue (2.7% margin) suggests profitability concerns despite scale
  • ! Operating cash flow of $5.5M leaves limited cushion for growth investments or shareholder returns
  • ! Operating margin of 3.2% is dangerously thin and vulnerable to any revenue decline
ChatGPT
  • ! Negative free cash flow and weak operating cash generation
  • ! Thin operating margin (2.9%) leaves little cushion for shocks
  • ! Potential working‑capital volatility creating earnings-to-cash flow disconnect

Key Metrics to Watch

Claude
  • * Operating margin trend - critical to determine if 3.2% can expand toward industry norms
  • * SG&A and R&D spending as percentage of revenue - understand drivers of the margin compression
  • * Free cash flow conversion - monitor if FCF margin can improve beyond 2.1%
ChatGPT
  • * Operating cash flow
  • * Operating margin

Lifevantage Corp (LFVN) Financial Metrics & Key Ratios

Revenue
$140.2M
Net Income
$3.8M
EPS (Diluted)
$0.30
Free Cash Flow
$2.9M
Total Assets
$62.1M
Cash Position
$12.5M

💡 AI Analyst Insight

The relatively thin 2.1% FCF margin may limit capital allocation flexibility.

LFVN Profit Margin, ROE & Profitability Analysis

Gross Margin 77.4%
Operating Margin 3.2%
Net Margin 2.7%
ROE 11.4%
ROA 6.1%
FCF Margin 2.1%

LFVN vs Healthcare Sector: How Lifevantage Corp Compares

How Lifevantage Corp compares to Healthcare sector averages

Net Margin
LFVN 2.7%
vs
Sector Avg 12.0%
LFVN Sector
ROE
LFVN 11.4%
vs
Sector Avg 15.0%
LFVN Sector
Current Ratio
LFVN 2.0x
vs
Sector Avg 2.0x
LFVN Sector
Debt/Equity
LFVN 0.0x
vs
Sector Avg 0.6x
LFVN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Lifevantage Corp Stock Overvalued? LFVN Valuation Analysis 2026

Based on fundamental analysis, Lifevantage Corp has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
11.4%
Sector avg: 15%
Net Profit Margin
2.7%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Lifevantage Corp Balance Sheet: LFVN Debt, Cash & Liquidity

Current Ratio
1.96x
Quick Ratio
1.04x
Debt/Equity
0.00x
Debt/Assets
46.3%
Interest Coverage
N/A
Long-term Debt
$0.0

LFVN Revenue & Earnings Growth: 5-Year Financial Trend

LFVN 5-year financial data: Year 2021: Revenue $232.9M, Net Income $7.4M, EPS $0.50. Year 2022: Revenue $232.9M, Net Income $11.5M, EPS $0.79. Year 2023: Revenue $213.4M, Net Income $3.1M, EPS $0.24. Year 2024: Revenue $213.4M, Net Income $2.5M, EPS $0.20. Year 2025: Revenue $228.5M, Net Income $2.9M, EPS $0.23.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Lifevantage Corp's revenue has remained relatively flat over the 5-year period, with a 2% decline. The most recent EPS of $0.23 reflects profitable operations.

LFVN Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
2.1%
Free cash flow / Revenue

LFVN Quarterly Earnings & Performance

Quarterly financial performance data for Lifevantage Corp including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2026 $43.7M $276.0K $0.11
Q2 2026 $48.9M $276.0K $0.02
Q1 2026 $47.2M $1.8M $0.14
Q3 2025 $48.2M $629.0K $0.13
Q2 2025 $51.6M -$27.0K $0.00
Q1 2025 $47.2M $629.0K $0.05
Q3 2024 $48.2M $574.0K $0.05
Q2 2024 $51.6M -$27.0K $0.00

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Lifevantage Corp Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$5.5M
Cash generated from operations
Stock Buybacks
$1.6M
Shares repurchased (TTM)
Capital Expenditures
$2.5M
Investment in assets
Dividends Paid
$1.7M
Returned to shareholders

LFVN SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Lifevantage Corp (CIK: 0000849146)

📋 Recent SEC Filings

Date Form Document Action
May 6, 2026 8-K lfvn-20260506.htm View →
May 6, 2026 10-Q lfvn-20260331.htm View →
Apr 16, 2026 8-K lfvn-20260413.htm View →
Apr 3, 2026 4 xslF345X06/ownership.xml View →
Apr 3, 2026 4 xslF345X06/ownership.xml View →

Frequently Asked Questions about LFVN

What is the AI rating for LFVN?

Lifevantage Corp (LFVN) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are LFVN's key strengths?

Claude: Revenue growth of 14.2% YoY shows market traction. Exceptional gross margin of 77.4% indicates strong product economics. ChatGPT: Debt‑free balance sheet with solid liquidity (current ratio 2.03x). High gross margin of 76.7% indicating strong unit economics.

What are the risks of investing in LFVN?

Claude: Severe 44.2 percentage point margin compression (gross to operating) indicates unsustainable cost structure or excessive operating expenses. Net income of only $3.8M on $140.2M revenue (2.7% margin) suggests profitability concerns despite scale. ChatGPT: Negative free cash flow and weak operating cash generation. Thin operating margin (2.9%) leaves little cushion for shocks.

What is LFVN's revenue and growth?

Lifevantage Corp reported revenue of $140.2M.

Does LFVN pay dividends?

Lifevantage Corp pays dividends, with $1.7M distributed to shareholders in the trailing twelve months.

Where can I find LFVN SEC filings?

Official SEC filings for Lifevantage Corp (CIK: 0000849146) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is LFVN's EPS?

Lifevantage Corp has a diluted EPS of $0.30.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is LFVN's fundamental grade?

Based on our AI fundamental analysis in May 2026, Lifevantage Corp has a B grade with 64% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is LFVN stock overvalued or undervalued?

Valuation metrics for LFVN: ROE of 11.4% (sector avg: 15%), net margin of 2.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is LFVN's AI grade for 2026?

Our dual AI analysis gives Lifevantage Corp a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is LFVN's free cash flow?

Lifevantage Corp's operating cash flow is $5.5M, with capital expenditures of $2.5M. FCF margin is 2.1%.

How does LFVN compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 2.7% (avg: 12%), ROE 11.4% (avg: 15%), current ratio 1.96 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 7, 2026 | Data as of: 2026-03-31 | Powered by Claude AI